Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 2 of 2 results for ta393

  1. Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA393)

    Evidence-based recommendations on alirocumab (Praluent) for treating primary hypercholesterolaemia or mixed dyslipidaemia in adults.

    Technology appraisal guidance
    Published
    22 June 2016
    View recommendations

    Sections for TA393

  2. Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides (TA805)

    Evidence-based recommendations on icosapent ethyl (Vazkepa) with statin therapy for reducing the risk of cardiovascular events in adults with raised triglycerides.

    Technology appraisal guidance
    Published
    13 July 2022
    View recommendations

    Sections for TA805